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Abstract
Background: Liver resection is considered to offer the only hope of cure for patients with liver malig-
nancy. However, there are concerns about its safety, particularly in view of the increasing efficacy of less
invasive strategies. No systematic review of prognostic research in liver resections has yet been
performed.
Methods: A systematic search identified articles published between 1999 and 2012 that performed a
risk prediction analysis in patients undergoing liver resection. Studies were included if an outcome
occurring within 90 days of surgery was identified, multivariable analysis performed and regression
coefficients provided. The main endpoints were the outcomes and predictors chosen by the investigators,
their definition, the performance and validity of the models, and the quality of the study as assessed using
the QUIPS (quality in prognosis studies) tool.
Results: A total of 91 studies were included. Eleven were prospective, but only two of these were
registered. Twenty-eight endpoints were identified. These focused on postoperative morbidity or mortal-
ity, but many were redundant or ill defined and other relevant patient-reported outcomes were lacking.
Predictors were not standardized, were poorly defined and overlapped. Only nine studies assessed the
performance of their models and seven made an internal or temporal validation, but none reported an
external validation or impact analysis. The median QUIPS score was 34 out of 50, indicating a high risk
for bias.
Conclusion: Prognostic research in liver resection is still at the developmental stage.
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Introduction
Since the mid-1990s liver resection has been considered the
optimal treatment and to offer the only hope of cure for patients
with primary liver malignancy or colorectal liver metastasis.1 This
supposition, however, has some limitations.
Firstly, liver resection is classified as a high-risk surgical pro-
cedure2 and there are still concerns about its safety.3 Lowmortality
rates published by some academic institutions match neither
those reported by prospective studies4 nor population-based rates,
which are 1.6-fold higher.5 Mortality rates have also remained
stable or have decreased only marginally over the past 20 years,
both at some high-volume academic units6 and at national levels.7
Morbidity rates have not declined and in the USA today, fewer
patients are discharged directly to their homes than in the past,8
which suggests that recovery has not improved. In addition, liver
surgeons do not accurately predict postoperative outcome.4
Secondly, innovative surgical strategies, such as portal vein
embolization,9,10 two-stage hepatectomy11,12 and associated liver
partition with portal vein ligation for staged hepatectomy,13 are
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being developed constantly to improve resection rates. However,
not only is there still no consensus on the definition of a resectable
tumour,14 but these new strategies are poorly evaluated and the
complexity of liver surgery has increased.
Thirdly – and this is likely to be attributable to perceptions of
the risk associated with the procedure and its potential benefit –
liver resections are performed inconsistently, as indicated by
highly variable national and regional rates of resection, which
have increased only marginally in recent years.15,16
Fourthly, medical oncology and interventional radiology pro-
cedures increasingly represent effective alternatives to liver resec-
tion. They are also less invasive in patients in whom quality of
life (QoL) (rather than simply quantity of life) is considered
the optimal endpoint in determinations of the best therapeutic
strategy.17
There are three possible reasons why both the associated risk
and the acceptance of liver resection appear to have reached a
plateau: the surgical procedure cannot be standardized beyond a
certain point; the endpoints used to assess risk (with regard to
benefit) are not adequate for the modern era, and the predictors of
these endpoints have not been identified or taken into account.
To address these issues, the present authors performed a sys-
tematic review to amalgamate the available literature on risk pre-
diction models developed in the setting of liver resection. The
aims of this process were to critically analyse: (i) the outcomes
chosen as endpoints, as well as their predictors, and (ii) the quality
of the studies and their models, as well as their suitability for
clinical use.
Materials and methods
Study design and identification
A systematic review was performed, in accordance with the
PRISMA (preferred reporting items for systematic reviews and
meta-analyses) Statement,18 to identify articles published during
the past decade that addressed the postoperative risk associated
with liver resection. An electronic search was formulated in
collaboration with a medical librarian. The syntax, which
included a previously validated strategy19 (Table S1, online), was
used in PubMed and the search was restricted to English-language
articles published between May 1999 and 31 March 2012. This
review is part of a larger registered research program
(clinicaltrials.gov: NCT01715402).
Eligibility criteria
To be eligible for inclusion, studies were required to meet the
following criteria: (i) an outcome (endpoint) considered by the
authors as a surrogate of the postoperative course must be iden-
tified; (ii) this outcome must be evaluated for up to 90 days after
surgery (i.e. early outcome); (iii) multivariable analysis must be
performed to identify independent predictors of this outcome;
(iv) the regression coefficient, or the odds ratio (OR), of the
predictors must be provided, and (v) the cohort must include at
least 100 patients (to allow for meaningful statistical analysis).20
Articles and data extraction
All titles and abstracts of the articles retrieved were reviewed by
two of the authors (CL and OF) independently. Duplicate articles
and those that obviously failed to meet the eligibility criteria were
removed. A full-text review of the remaining articles was per-
formed to exclude duplicates and check eligibility. In the event of
disagreement, a final decision was reached by consensus. To tri-
angulate the search, the reference lists of all retained articles were
checked for additional papers that might have been missed in the
initial search.
Data extracted from retained articles included: the names of the
first author, corresponding author and institution; year of publi-
cation; country of origin; design of study and statistical analysis;
method of data collection (retrospective or prospective); study
period; sample size; indication(s) for hepatectomy; outcomes
measured and their definitions; predictors and their definitions,
and ORs. Data required for quality assessment (see below) were
also recorded. To identify registered studies (registration of prog-
nostic research has been recommended21), the website http://
www.clinicaltrials.gov was screened using the names of the first
and corresponding authors.
Data analysis and definitions
Endpoints and predictors for each study were identified and their
definitions compared across studies. A predictor was defined as:
(i) a ‘candidate predictor’ if the variable had been considered in
the multivariable analysis performed to identify independent risk
factors of the given outcome, and (ii) an ‘independent predictor’ if
the variable was found to be independent in multivariable analy-
sis. Predictors were grouped in appropriate categories (preopera-
tive, intraoperative and postoperative). Independent predictors in
each study were listed and all studies were subsequently screened
to identify the number of studies in which each predictor had
been considered as a candidate predictor. Studies in which a risk
prediction model had been developed were identified and the
performance of the model, as well as the method used to validate
the model, was recorded. As the studies were heterogeneous in
terms of design and methodology, data pooling and meta-analysis
were not performed.
Quality assessment
The quality of each study was assessed according to risk for bias
using the QUIPS (quality in prognosis studies) tool.22 This is based
on the identification of five domains of potential study bias (study
participation, prognostic factor measurement, outcome measure-
ment, confounding factor measurement, and analysis) with three
to seven items per domain (Table S2, online). Each item is given a
score according to whether its quality limits potential bias: a score
of 2 indicates that it does; a score of 1 indicates that it does so
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‘partly’, and a score of 0 indicates that it does not. Data were
extracted independently by the authors and disagreements
resolved by discussion.
Results
Selected studies
The electronic search identified 1407 potentially relevant articles.
Figure 1 shows a flow diagram of the studies excluded and
included. A total of 91 studies met the eligibility criteria (Appen-
dix S1, online) and were included in the review.
Characteristics of the selected studies
Fifty-five studies originated from Western and 36 from Eastern
countries (Table 1). Seventy-nine studies were conducted using
data extracted from clinical notes and 12 were based on regional
or national administrative data. Of those based on clinical notes,
21 studies (27%) had collected the patient cohort over a period of
less than 5 years, and 32 (41%) had collected the cohort over more
than 10 years or did not specify the duration of inclusion. All of
the studies that relied on administrative data originated in North
America. The median number of patients in series for which data
were sourced from clinical notes was 266, whereas the median
number of patients in series that used administrative data was
2834. Eight of the 79 studies based on clinical notes were
multicentre studies. Study design was described as prospective in
11 studies, but only two had been registered. Data collection in
notes-based studies was described as prospective in 72 studies;
however, none described (or had previously published) the full list
of items recorded. Baseline characteristics of the included studies
are summarized in Table S3 (online).
Endpoints
A total of 28 distinct postoperative endpoints were identified
(Table 2). The most frequent related to overall morbidity, overall
mortality or liver failure. Only five studies used hospital length of
stay (LoS) as an endpoint, and none considered QoL, hospital
readmission, or if and when adjuvant chemotherapy could be
initiated in patients with colorectal liver metastases.
Table 2 also summarizes the definitions of these endpoints.
Mortality was defined in 27 of 29 studies (93%), but six distinct
definitions were used. Overall morbidity was defined (at least
vaguely) in 33 of 43 studies (77%), but only 16 used a severity
grading scale. Specific complications were usually defined, but the
definitions were highly variable from one study to another. For
example, liver failure was defined in 18 of the 21 studies that used
this as an endpoint, but 11 different definitions were used. Simi-
larly, of the five studies that used biliary leak as an endpoint, one
did not define this complication and the other four employed
different definitions. When stated, the timeframe for the occur-
rence of an endpoint was short: for example, only two studies and
one study reported 90-day mortality and morbidity, respectively.
Predictors
In the 29 studies that used postoperative mortality as the outcome
measure, a total of 43 distinct independent predictors were
1407 records identified through database searching 
155 full-text articles assessed
for eligibility
64 full-text articles excluded  for:
lacking multivariable analysis
lacking independent variables
on multivariable analysis
lacking odds ratios
1252 records excluded on the
basis of title and abstract 
91 studies included in
analysis
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Figure 1 Flow diagram showing the selection of studies performing a risk prediction analysis in patients submitted to liver resection for
systematic review
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identified (Table 3). However, most overlapped and were related
to patient age, comorbidities, operation type, and blood loss or
intraoperative transfusion. These variables were not indepen-
dently associated with mortality in all studies and, when they
were, the associated ORs were highly variable.
From the 43 studies that used overall postoperative morbidity
as the outcome measure, 51 distinct independent predictors were
identified (Table 4). As with predictors of mortality, most over-
lapped and were related to patient age, comorbidities, operation
type, and blood loss or intraoperative transfusion. Results were
inconsistent in terms of independent associations with morbidity
and ORs.
For both mortality and morbidity, variables relating to nutri-
tional status or intraoperative events were hardly investigated, or
not at all.
Independent predictors of 25 distinct endpoints are summa-
rized in Table S4 (online).
Model presentation
Although ORs (rather than regression coefficients) for the predic-
tors were reported, none of the studies provided the intercept of
the regression equation and thus readers are unable to calculate
risk predictions for their own patients. Six of the 91 studies (7%),
originating from three groups, presented their prognostic model
as a simplified prediction score by transforming the regression
coefficient into points.23–28
Model development
Nine studies (10%) assessed the predictive performance of their
models in terms of calibration (agreement between observed and
predictive endpoints) or discrimination (between patients with or
without the outcome).24–32 Seven (8%) of the 91 studies carried
out some form of validation of a risk prediction model, including
six with internal validation23–28 and one with temporal valida-
tion.33 In the latter study, however, patient selection differed
Table 1 Summary of studies performing a risk prediction analysis in patients submitted to liver resection included for review
All studies Studies based on
clinical data
Studies based on
administrative data
Studies, n 91 79 12
Origin, n
Western seriesa 55 43 12
Eastern series 36 36 0
Data sources, n
Clinical database 79 79 0
Administrative database 12 0 12
Study design, n
Prospective 11 11 0
Retrospective 80 68 12
Data collection, n
Prospective 84 72 12
Retrospective 6 6 0
Unclear 1 1 0
Number of patients, median (range) 323 (99–50 537) 266 (99–1803) 2834 (569–50 537)
Inclusion period, n
<5 years 27 21 6
5–10 years 33 27 6
>10 years 28 28 0
Unclear 4 4 0
Indications for surgery, n
Malignancy 52 46 6
Benign disease 1 1 0
Benign and malignant diseases 31 25 6
Benign, malignancy, living donor 4 4 0
Living donor 2 2 0
Unclear 1 0 1
aUSA, Europe, Canada and New Zealand.
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somewhat from that in the development sample. A summary of
these models is provided in Table S5 (online).
There was no impact study quantifying the effect of using a
prognostic model on doctor behaviour, patient outcome or the
cost-effectiveness of care in comparison with not using such a
model.
Quality assessment
The median QUIPS score for the included studies was 34 (range:
24–41) of a maximum score of 50 (Table 5). The highest risks for
bias were observed for the domains of confounding factor meas-
urement and study participation.
Discussion
Statement of principal findings
Liver resection is a high-risk treatment.3 Risk is a subjective
concept used to determine the nature, likelihood and acceptability
of the harm associated with a choice or an intervention.34 The aim
of this systematic review was to amalgamate the literature on how
the risk associated with liver resection has been perceived and
evaluated. A large number of studies were identified, but their
quality and transferability were globally poor because of a number
of methodological shortcomings.
Strengths and limitations of the review
There is increasing interest in the reporting of early outcomes
following liver resection.35 Recent systematic reviews have sum-
marized current rates of mortality, total morbidity and specific
complications,36 or surrogate endpoints that could be used to
substitute for a clinically meaningful endpoint.37 However, to the
best of the present authors’ knowledge, this is the first study to
review the full range of endpoints analysed, their predictors, and
the quality of published series.
This study has inherent limitations. Firstly, some articles may
have been missed, although the search strategy used has been
validated.19 Secondly, the criteria used to assess the quality of
studies are semi-quantitative and, in the present study, are occa-
sionally subject to interpretation as these were seldom clearly
addressed in the Methods sections of the included articles.
Thirdly, standardized definitions of liver failure, biliary leak and
haemorrhage after liver resection were published in 2011;38–40 it is
therefore possible that, over the past 2 years, definitions of at least
some endpoints have improved. However, these definitions have
either not yet been validated or already appear controversial.41
Limitations of studies included in the review
Study population
Data used to develop a prognostic model should ideally come
from a prospective cohort that has been designed to resolve a
specific research question.42 In this review, although data were
generally described as having been collected prospectively, only
12% of studies were designed prospectively, only two appeared to
have been registered, and none described precisely the full range
Table 2 Endpoints in studies performing a risk prediction analysis in
patients submitted to liver resection
Endpointe Studies
assessing
the endpoint
of interest, n
Studies
defining
the endpoint
of interest, n
Mortality
Overall mortality 29 27a
Mortality from liver failure 3 3
Morbidity
Overall morbidity 43 33b
Severe morbidity 7 6
Organ dysfunction 1 1
Major infectious morbidity 1 1
Intraoperative complications
Operation time 1 1
Intraoperative blood transfusion 1 1
Liver-related complications
Hepatobiliary complications 1 1
Haemorrhage 1 1
Biliary complications 1 1
Liver failure 21 18c
Bile leak 5 4d
Biliary complications 1 1
Ascites 1 1
Acute renal failure 1 1
Pulmonary complications 1 1
Pleural effusion 1 1
Pneumonia 1 1
Pulmonary embolism 1 1
Infection 6 6
Surgical site infection 2 2
Intra-abdominal abscess 1 1
Blood transfusion during
hospital stay
1 1
Systemic complications 1 1
Postoperative complications
Ventilation for >48 h 1 1
Reoperation 1 1
Length of stay 5 5
aSix definitions of mortality were used, including 30-, 60- and 90-day,
operative and in-hospital mortality and any death after surgery.
bMultiple definitions of morbidity (when morbidity was defined) were used
depending on severity (major as opposed to minor, specific, serious,
resulting in organ failure, graded 3–5 on a scale of 1–5) origin (medical,
surgical, both or unspecified) and timing (30-, 60- or 90-day, operative,
in-hospital and after surgery).
cLiver failure was defined by the association of many parameters includ-
ing serum bilirubin, serum lactate, international normalized ratio, pro-
thrombin time, encephalopathy, ascites, pleural effusion, varix, and time
and delay of occurrence.
dBile leak was defined by the association of many parameters including
level of bilirubin and delay in occurrence.
eSome studies analysed one or more endpoints of interest.
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Table 3 Variables predictive of overall postoperative mortality in studies performing a risk prediction analysis in patients submitted to liver
resection
Variable Studies including this variable
in multivariable analysis, n
Studies showing this variable
to be independent, n
Odds ratio
Median (range)
Preoperative variables
Demographics
Sex 22 3 1.61 (1.44–1.69)
Age 27 12 1.80 (1.03–4.83)
Race 1 1 2.15
Insurance status 3 2 2.35 (1.80–2.90)
Coexisting conditions
Number/presence of comorbidities 10 2 1.28 (1.25–1.31)
Comorbidity 2 2 2.47 (1.38–3.56)
Charlson score 4 4 5.20 (1.50–7.17)
Chronic renal disease 5 1 24.00
Chronic pulmonary disease 2 1 2.70
Obesity 1 1 1.83
Admission (elective/not elective) 8 2 3.40 (3.04–3.75)
Indication or stage
Biliary cancer 1 1 3.02
HCC on cirrhosis 1 1 11.55
Primary cancer 21 3 1.81 (1.61–3.00)
Growth pattern of HCC 1 1 2.22
Liver function or biological tests
Galactose eliminating capacity 1 1 1.23
ICG of future remnant liver 1 1 8.06
Cirrhosis 12 4 6.50 (3.28–54.09)
Underlying liver disease 3 3 7.00 (2.00–7.20)
Child–Pugh grade 4 1 2.42
Thrombopoenia 9 4 5.92 (0.99–12.50)
Hypoalbuminaemia 6 2 3.22 (2.15–4.3)
Increased bilirubin 9 2 1.20 (1.10–1.30)
Increased creatinine 5 2 2.44 (1.01–3.86)
Study period 1 1 4.58
Hospital factors
Low hospital volume 4 4 1.80 (1.66–3.10)
Non-teaching hospital 3 3 1.43 (1.42–1.95)
Liver transplant unit 1 1 1.70
Intraoperative variables
Operation type
Extent of resection 5 2 11.67 (6.43–16.90)
Major hepatectomy 7 3 1.82 (1.57–2.26)
Percentage of volume resected 1 1 1.04
Number of segments resected 4 2 1.44 (1.42–1.45)
One lobe or more resected 6 5 3.90 (2.20–4.90)
Complex hepatectomy 1 1 2.18
Associated procedures
Associated procedure 4 1 2.35
Associated colon resection 6 1 5.40
Surgical factors
Blood transfusion 14 6 3.36 (2.05–10.22)
Blood loss 9 4 1.55 (1.18–1.89)
Postoperative variables
Liver function
Increased INR 2 1 3.68
Increased bilirubin 2 1 10.80
50/50 day 5 2 2 122.50 (29.40–215.60)
50/50 day 3 1 1 12.70
Sepsis 1 1 37.58
HCC, hepatocellular carcinoma; ICG, indocyanine green clearance test; INR, international normalized ratio.
50/50 defined by the association of a prothrombin time of <50% and serum bilirubin of >50 μmol/l on postoperative day 5.
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Table 4 Variables predictive of overall postoperative morbidity in studies performing a risk prediction analysis in patients submitted to liver
resection
Variable Studies including the
variable in multivariable
analysis, n
Studies showing
this variable to
be independent, n
Odds ratio
Median (range)
Preoperative variables
Demographics
Sex 22 2 1.72 (1.38–2.06)
Age 23 5 1.02 (1.02–1.66)
Coexisting conditions
ASA score 4 2 5.15 (1.53–8.77)
Number/presence of comorbidities 5 3 1.65 (1.40–3.95)
Obesity 3 1 1.24
Cardiovascular disease 2 1 1.25
Previous cardiac operation 1 1 2.82
Severe chronic obstruction pulmonary disease 2 1 2.41
Indication or stage
HCC on cirrhosis 1 1 2.30
Malignancy 14 2 5.90 (3.33–8.47)
Liver function or biological tests
Galactose elimination capacity 1 1 2.05
Underlying liver disease 3 1 1.60
Cirrhosis 6 2 3.43 (3.37–3.49)
Steatosis 4 2 1.36 (1.24–1.47)
Child–Pugh grade B/C 9 1 5.00
Portal hypertension 1 1 2.02
Increased ICG-R15 value 11 1 6.03
Thrombopoenia 5 4 2.64 (1.67–4.65)
Hypoalbuminaemia 12 5 1.58 (1.15–3.72)
Increased creatinine 2 1 1.78
Increased GGT 3 1 8.59
Increased liver enzymes 8 2 1.81 (1.63–1.99)
Decreased prothrombin time 10 1 7.50
Increased hepatocyte growth factor 1 1 12.56
Increased hyaluronic acid level 1 1 1.80
Study period 3 1 2.45
Previous medical history
Chemotherapy 5 1 2.40
Cholangitis 1 1 9.08
Previous hepatic resection 1 1 3.84
Preoperative nutrition
Sarcopoenia 1 1 3.12
Intraoperative variables
Operation type
Extent of resection 2 2 1.37 (1.17–1.56)
Major hepatectomy 15 4 3.20 (1.43–5.88)
Number of segments resected 4 4 1.51 (1.20–10.94)
One lobe or more resected 2 2 2.16
Resected liver volume 1 1 7.00
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of variables recorded. Most were retrospective studies, in which
the control that investigators have over data collection, which may
be incomplete, inaccurate or inconsistently measured, is inher-
ently limited. The accrual period was longer than 10 years or
undefined in 40% of the studies. This is of concern as the study
period was independently correlated with outcome in several
studies,43–45 which suggests the influence of unidentified con-
founders, such as improved patient selection, instrumentation or
management.
Starting point
Submission to liver resection was the starting point of all studies.
This excludes from prognostic analysis patients who were consid-
ered unfit for surgery or those in whom surgery was aborted. The
reasons for this selection (bias) were not addressed and are at least
partly subjective, rather than merely objective.46 Population-based
or multicentre-based studies may, to some extent, overcome this
limitation, but these were rare.
Endpoints and predictors
Endpoints frequently had imprecise definitions, which were
inconsistent among studies; for example, mortality was defined as
operative, in-hospital, or as 30-, 60- or 90-day mortality. This
is a concern as in-hospital or 30-day mortality captures only
approximately half the events obtained using 90-day mortality.16,47
There was similarly a lack of standardized definition of predictors.
For example, the extent of surgery was expressed in six different
ways, which may indicate that the classical definition of a
major hepatectomy (resection of three or more segments) is not
considered appropriate.48 Similarly, definitions of comorbidities
were quite general and subjective, rather than relying on tests
of function or physiological reserve. The handling of continuous
variables was also of concern. It was generally assumed that
they were linearly correlated with the outcome. This was,
however, not checked, and continuous variables frequently
require modelling.49 When transformed into categorical variables,
the threshold value (defining the groups) was frequently
chosen arbitrarily and not defined according to best sensitivity
and specificity.
Model development
A number of studies were excluded from analysis because they
provided only P-values and not regression coefficients (or ORs)
linking predictors to outcome. Assessment of the performance of
models was infrequent and, as none of the models underwent
external validation, their generalizability is unknown.50 No study
investigated the impact of a prognostic model on clinical practice
or outcome.
Table 4 Continued
Variable Studies including the
variable in multivariable
analysis, n
Studies showing
this variable to
be independent, n
Odds ratio
Median (range)
Right/extended right hepatectomy 2 1 2.78
Repeat hepatectomy 3 1 2.42
Palliative resection 1 1 2.57
Associated procedures
Associated procedure 4 1 2.14
Associated biliary procedures 2 1 2.84
Associated vascular resection 2 1 2.10
Synchronous bowel procedures 1 1 16.11
Extrahepatic procedures 2 1 3.45
Surgical factors
Blood loss 18 14 1.83 (1.22–17.10)
Blood transfusion 16 13 2.52 (1.2–10.78)
Length of surgery 13 5 1.85 (1.01–5.22)
Pringle manoeuvre 10 4 2.28 (1.40–2.90)
Abdominal drainage 4 1 4.44
Thoracoabdominal incision 2 1 1.96
Postoperative variables
Increased bilirubin 2 1 83.30
Decreased cholinesterase B 1 1 2.20
ASA, American Society of Anesthesiologists; GGT, gamma-glutamyl transferase; HCC, hepatocellular carcinoma; ICG-R15, indocyanine green
retention rate at 15 min.
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Interpretation with reference to other studies
Endpoints
The outcome measures in the included studies essentially referred
to postoperative overall morbidity, overall mortality and liver
failure. Postoperative mortality is of particular relevance at a time
when less invasive treatment strategies are becoming increasingly
effective. In terms of risk prediction, however, reported mortality
rates were low in the specialized centres that contributed most to
this review (i.e. the number of events for statistical analysis was
limited), were captured inconsistently (i.e. they were usually
assessed as in-hospital or 30-day events),15 and causes of death
were not detailed (postoperative death is multifactorial and
reflects adverse events, inappropriate indications or failure to
cure). This may explain why, except for patients with severe
underlying cirrhosis, high-risk groups are still poorly defined,
although they do exist.51
The outcome of postoperative morbidity is also potentially rel-
evant as it may result in sequelae or increased expenditure,52 or
may adversely impact on survival53,54 or QoL.55 However, morbid-
ity was assessed mainly in terms of overall occurrence, whereas the
spectrum of adverse events is wide56 and does not necessarily
correlate with common predictors. There was also considerable
interest in postoperative liver failure, although its definition was
not standardized and it has become extremely rare.57 Recently, it
has been suggested that the severity of complications should be
graded objectively,58 that composite endpoints might be used,36
and that complications should be reported more comprehen-
sively,59 which was infrequently the case. The performance of root
Table 5 Assessment of quality score of studies performing a risk prediction analysis in patients submitted to liver resection
Quality score
Median (range)
Maximum
score
Study participation 6 (2–9) 10
Population described for key characteristics 1 2
Sampling and recruitment described 2 2
Inclusion/exclusion criteria described 1 2
Adequate participation 2 2
Baseline study sample described 1 2
Prognostic factor measurement 9 (4–10) 12
Prognostic factors are clearly described or defined 2 2
Continuous variables reported, or appropriate cut-off points used 1 2
Prognostic factors are valid and reliable 2 2
Study sample has complete data for prognostic factors 2 2
Same method and setting of measurement for all study participants 2 2
Appropriate methods used for missing prognostic data 0 2
Outcome measurement 4 (0–6) 6
Definition of the outcome described 2 2
Outcome measure and method are valid and reliable 1 2
Same method and setting of measurement for all study participants 1 2
Confounding factor measurement 8 (4–10) 14
Important confounders are measured 1 2
Clear definitions of confounders described 2 2
Measurement of all confounders is valid and reliable 1 2
Same method and setting of measurement for all study participants 2 2
Appropriate methods used for missing confounder data 0 2
Important confounders accounted for in the study design 1 2
Important confounders accounted for in the analysis 1 2
Analysis 7 (4–8) 8
Sufficient presentation of data to assess the adequacy of the analysis 1 2
Strategy for model building appropriate and based on a conceptual model 2 2
Adequate selection of model for the design of the study 2 2
No selective reporting of results 2 2
Median quality score of studies 34 (24–41) 50
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cause analysis of adverse events, as initiated recently in pancreatic
surgery,60 as well as a focus on the direct and indirect conse-
quences of complications rather than on complications them-
selves, are also required.
By contrast with postoperative mortality and morbidity, a
number of other clinically relevant endpoints were not or were
only seldom addressed. These included, in particular, LoS, success
of the operation, ability to receive adjuvant treatment in due
course, ability to return to work, and QoL. Provided it is assessed
in conjunction with hospital readmission, which is a major
concern,61 LoS is highly relevant in the current context of
laparoscopic resections, enhanced recovery after surgery (ERAS)
protocols62 and, more broadly, day case surgery, for which there is
increasing administrative demand.63 Quality of life is coming to
represent the main endpoint in some medical or low-risk surgical
trials, and there is little reason why high-risk surgery should
escape this trend.
These results suggest that the investigators in these studies, as
surgeons, focused on technique and perioperative misadventure,
but failed, as doctors, to take account of patients’ or families’
expectations, or of the environment in which they work as sur-
geons, which includes other specialist physicians (such as anaes-
thetists and oncologists) and administrators.64 The ensuing risks
are those of surgeon isolation, which inevitably results in the
performance of a ‘more comprehensive’, ‘objective’ assessment of
risk by third parties.
Predictors
Most of the variables tested for their possible association with
endpoints focused on readily available preoperative and
intraoperative data, particularly comorbid conditions and extent
of liver resection.As currently characterized, coexisting conditions
failed to predict outcome reliably. This was particularly the case
for the American Society of Anesthesiologists (ASA) grade, which
underlines the subjectivity of this score.65 The present study also
failed to provide evidence that indocyanine green (ICG) clearance
predicts outcome and thus does not elucidate why this test is used
routinely in Eastern countries and sparingly in the West.66,67
There was a surprising deficit in the evaluation of some preop-
erative or intraoperative variables. Preoperative nutritional status,
for example, was rarely evaluated, although it has been linked
consistently to an increase in postoperative complications.68
Intraoperative variables other than extent of surgery (with the
limitations addressed above) were restricted to blood loss and its
prevention by vascular clamping, whereas the patient’s
haemodynamic profile, body temperature, receipt of pharmaceu-
tical agents and other anaesthetic-related parameters were largely
overlooked.
The high number of predictors identified in this review,most of
which overlap, also suggests that the investigators’ policy was to
design new models, rather than using their data to test or modify
existing models; this strategy is not recommended.42
Recommendations
This review shows that prognostic model research in the context
of liver resection is still at the developmental stage,69 which does
not allow for reliable patient counselling, the design and assess-
ment of surgical innovation, the development of trials or decision
models, or the comparison of performance between centres or
alternative treatment options.70 This is of concern at a time of
emphasis on the use of surgical decision aids17 and evaluation of
innovations,66 of evolving vision of primary care and research,71
and of increasing mandatory public reporting of hospital and
surgeon outcomes.72
Steps for improving the quality of prognostic research have
been updated.21,73 In the context of liver surgery, these involve, in
particular, performing prospectively designed and registered
studies, using standardized endpoints (either alone or in combi-
nation)36 and assessing their severity59 and predictors in a clearly
defined, multicentre population, and encouraging the perfor-
mance of validation and impact studies.
The goal of liver resection has evolved over time. Initially, the
aim was for the patient to survive the procedure. With the devel-
opment of living related-donor liver graft harvesting, the goal has
been to minimize complications. Today’s ambition for liver
surgery should probably be to rephrase its objectives, taking into
account patient-reported outcomes74 and the fact that surgery is
increasingly part of wider, multidisciplinary management.
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